Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer

Masanori Kawakami, Lisa Maria Mustachio, Jaime Rodriguez-Canales, Barbara Mino, Jason Roszik, Pan Tong, Jing Wang, J. Jack Lee, Ja Hye Myung, John V. Heymach, Faye M. Johnson, Seungpyo Hong, Lin Zheng, Shanhu Hu, Pamela Andrea Villalobos, Carmen Behrens, Ignacio Wistuba, Sarah Joy Spinella, Xi Liu, Ethan Dmitrovsky

Research output: Contribution to journalArticle

Abstract

Background: The first generation CDK2/7/9 inhibitor seliciclib (CYC202) causes multipolar anaphase and apoptosis in lung cancer cells with supernumerary centrosomes (known as anaphase catastrophe). We investigated a new and potent CDK2/9 inhibitor, CCT68127 (Cyclacel).

Methods: CCT68127 was studied in lung cancer cells (three murine and five human) and control murine pulmonary epithelial and human immortalized bronchial epithelial cells. Robotic CCT68127 cell-based proliferation screens were used. Cells undergoing multipolar anaphase and inhibited centrosome clustering were scored. Reverse phase protein arrays (RPPAs) assessed CCT68127 effects on signaling pathways. The function of PEA15, a growth regulator highlighted by RPPAs, was analyzed. Syngeneic murine lung cancer xenografts (n = 4/group) determined CCT68127 effects on tumorigenicity and circulating tumor cell levels. All statistical tests were two-sided.

Results: CCT68127 inhibited growth up to 88.5% (SD = 6.4%, P < .003) at 1 μM, induced apoptosis up to 42.6% (SD = 5.5%, P < .001) at 2 μM, and caused G1 or G2/M arrest in lung cancer cells with minimal effects on control cells (growth inhibition at 1 μM: 10.6%, SD = 3.6%, P = .32; apoptosis at 2 μM: 8.2%, SD = 1.0%, P = .22). A robotic screen found that lung cancer cells with KRAS mutation were particularly sensitive to CCT68127 ( P = .02 for IC 50 ). CCT68127 inhibited supernumerary centrosome clustering and caused anaphase catastrophe by 14.1% (SD = 3.6%, P < .009 at 1 μM). CCT68127 reduced PEA15 phosphorylation by 70% (SD = 3.0%, P = .003). The gain of PEA15 expression antagonized and its loss enhanced CCT68127-mediated growth inhibition. CCT68127 reduced lung cancer growth in vivo ( P < .001) and circulating tumor cells ( P = .004). Findings were confirmed with another CDK2/9 inhibitor, CYC065.

Conclusions: Next-generation CDK2/9 inhibition elicits marked antineoplastic effects in lung cancer via anaphase catastrophe and reduced PEA15 phosphorylation.

Original languageEnglish (US)
JournalJournal of the National Cancer Institute
Volume109
Issue number6
DOIs
StatePublished - Jun 1 2017
Externally publishedYes

Fingerprint

Anaphase
Lung Neoplasms
Centrosome
Circulating Neoplastic Cells
Growth
Protein Array Analysis
Robotics
Apoptosis
Cluster Analysis
Phosphorylation
Heterografts
Antineoplastic Agents
Epithelial Cells
Cell Proliferation
Lung
Mutation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kawakami, M., Mustachio, L. M., Rodriguez-Canales, J., Mino, B., Roszik, J., Tong, P., ... Dmitrovsky, E. (2017). Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. Journal of the National Cancer Institute, 109(6). https://doi.org/10.1093/jnci/djw297

Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. / Kawakami, Masanori; Mustachio, Lisa Maria; Rodriguez-Canales, Jaime; Mino, Barbara; Roszik, Jason; Tong, Pan; Wang, Jing; Lee, J. Jack; Myung, Ja Hye; Heymach, John V.; Johnson, Faye M.; Hong, Seungpyo; Zheng, Lin; Hu, Shanhu; Villalobos, Pamela Andrea; Behrens, Carmen; Wistuba, Ignacio; Spinella, Sarah Joy; Liu, Xi; Dmitrovsky, Ethan.

In: Journal of the National Cancer Institute, Vol. 109, No. 6, 01.06.2017.

Research output: Contribution to journalArticle

Kawakami, M, Mustachio, LM, Rodriguez-Canales, J, Mino, B, Roszik, J, Tong, P, Wang, J, Lee, JJ, Myung, JH, Heymach, JV, Johnson, FM, Hong, S, Zheng, L, Hu, S, Villalobos, PA, Behrens, C, Wistuba, I, Spinella, SJ, Liu, X & Dmitrovsky, E 2017, 'Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer', Journal of the National Cancer Institute, vol. 109, no. 6. https://doi.org/10.1093/jnci/djw297
Kawakami M, Mustachio LM, Rodriguez-Canales J, Mino B, Roszik J, Tong P et al. Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. Journal of the National Cancer Institute. 2017 Jun 1;109(6). https://doi.org/10.1093/jnci/djw297
Kawakami, Masanori ; Mustachio, Lisa Maria ; Rodriguez-Canales, Jaime ; Mino, Barbara ; Roszik, Jason ; Tong, Pan ; Wang, Jing ; Lee, J. Jack ; Myung, Ja Hye ; Heymach, John V. ; Johnson, Faye M. ; Hong, Seungpyo ; Zheng, Lin ; Hu, Shanhu ; Villalobos, Pamela Andrea ; Behrens, Carmen ; Wistuba, Ignacio ; Spinella, Sarah Joy ; Liu, Xi ; Dmitrovsky, Ethan. / Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. In: Journal of the National Cancer Institute. 2017 ; Vol. 109, No. 6.
@article{dc27a90f23df48ff9cecd9a966c3a8bb,
title = "Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer",
abstract = "Background: The first generation CDK2/7/9 inhibitor seliciclib (CYC202) causes multipolar anaphase and apoptosis in lung cancer cells with supernumerary centrosomes (known as anaphase catastrophe). We investigated a new and potent CDK2/9 inhibitor, CCT68127 (Cyclacel).Methods: CCT68127 was studied in lung cancer cells (three murine and five human) and control murine pulmonary epithelial and human immortalized bronchial epithelial cells. Robotic CCT68127 cell-based proliferation screens were used. Cells undergoing multipolar anaphase and inhibited centrosome clustering were scored. Reverse phase protein arrays (RPPAs) assessed CCT68127 effects on signaling pathways. The function of PEA15, a growth regulator highlighted by RPPAs, was analyzed. Syngeneic murine lung cancer xenografts (n = 4/group) determined CCT68127 effects on tumorigenicity and circulating tumor cell levels. All statistical tests were two-sided.Results: CCT68127 inhibited growth up to 88.5{\%} (SD = 6.4{\%}, P < .003) at 1 μM, induced apoptosis up to 42.6{\%} (SD = 5.5{\%}, P < .001) at 2 μM, and caused G1 or G2/M arrest in lung cancer cells with minimal effects on control cells (growth inhibition at 1 μM: 10.6{\%}, SD = 3.6{\%}, P = .32; apoptosis at 2 μM: 8.2{\%}, SD = 1.0{\%}, P = .22). A robotic screen found that lung cancer cells with KRAS mutation were particularly sensitive to CCT68127 ( P = .02 for IC 50 ). CCT68127 inhibited supernumerary centrosome clustering and caused anaphase catastrophe by 14.1{\%} (SD = 3.6{\%}, P < .009 at 1 μM). CCT68127 reduced PEA15 phosphorylation by 70{\%} (SD = 3.0{\%}, P = .003). The gain of PEA15 expression antagonized and its loss enhanced CCT68127-mediated growth inhibition. CCT68127 reduced lung cancer growth in vivo ( P < .001) and circulating tumor cells ( P = .004). Findings were confirmed with another CDK2/9 inhibitor, CYC065.Conclusions: Next-generation CDK2/9 inhibition elicits marked antineoplastic effects in lung cancer via anaphase catastrophe and reduced PEA15 phosphorylation.",
author = "Masanori Kawakami and Mustachio, {Lisa Maria} and Jaime Rodriguez-Canales and Barbara Mino and Jason Roszik and Pan Tong and Jing Wang and Lee, {J. Jack} and Myung, {Ja Hye} and Heymach, {John V.} and Johnson, {Faye M.} and Seungpyo Hong and Lin Zheng and Shanhu Hu and Villalobos, {Pamela Andrea} and Carmen Behrens and Ignacio Wistuba and Spinella, {Sarah Joy} and Xi Liu and Ethan Dmitrovsky",
year = "2017",
month = "6",
day = "1",
doi = "10.1093/jnci/djw297",
language = "English (US)",
volume = "109",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer

AU - Kawakami, Masanori

AU - Mustachio, Lisa Maria

AU - Rodriguez-Canales, Jaime

AU - Mino, Barbara

AU - Roszik, Jason

AU - Tong, Pan

AU - Wang, Jing

AU - Lee, J. Jack

AU - Myung, Ja Hye

AU - Heymach, John V.

AU - Johnson, Faye M.

AU - Hong, Seungpyo

AU - Zheng, Lin

AU - Hu, Shanhu

AU - Villalobos, Pamela Andrea

AU - Behrens, Carmen

AU - Wistuba, Ignacio

AU - Spinella, Sarah Joy

AU - Liu, Xi

AU - Dmitrovsky, Ethan

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background: The first generation CDK2/7/9 inhibitor seliciclib (CYC202) causes multipolar anaphase and apoptosis in lung cancer cells with supernumerary centrosomes (known as anaphase catastrophe). We investigated a new and potent CDK2/9 inhibitor, CCT68127 (Cyclacel).Methods: CCT68127 was studied in lung cancer cells (three murine and five human) and control murine pulmonary epithelial and human immortalized bronchial epithelial cells. Robotic CCT68127 cell-based proliferation screens were used. Cells undergoing multipolar anaphase and inhibited centrosome clustering were scored. Reverse phase protein arrays (RPPAs) assessed CCT68127 effects on signaling pathways. The function of PEA15, a growth regulator highlighted by RPPAs, was analyzed. Syngeneic murine lung cancer xenografts (n = 4/group) determined CCT68127 effects on tumorigenicity and circulating tumor cell levels. All statistical tests were two-sided.Results: CCT68127 inhibited growth up to 88.5% (SD = 6.4%, P < .003) at 1 μM, induced apoptosis up to 42.6% (SD = 5.5%, P < .001) at 2 μM, and caused G1 or G2/M arrest in lung cancer cells with minimal effects on control cells (growth inhibition at 1 μM: 10.6%, SD = 3.6%, P = .32; apoptosis at 2 μM: 8.2%, SD = 1.0%, P = .22). A robotic screen found that lung cancer cells with KRAS mutation were particularly sensitive to CCT68127 ( P = .02 for IC 50 ). CCT68127 inhibited supernumerary centrosome clustering and caused anaphase catastrophe by 14.1% (SD = 3.6%, P < .009 at 1 μM). CCT68127 reduced PEA15 phosphorylation by 70% (SD = 3.0%, P = .003). The gain of PEA15 expression antagonized and its loss enhanced CCT68127-mediated growth inhibition. CCT68127 reduced lung cancer growth in vivo ( P < .001) and circulating tumor cells ( P = .004). Findings were confirmed with another CDK2/9 inhibitor, CYC065.Conclusions: Next-generation CDK2/9 inhibition elicits marked antineoplastic effects in lung cancer via anaphase catastrophe and reduced PEA15 phosphorylation.

AB - Background: The first generation CDK2/7/9 inhibitor seliciclib (CYC202) causes multipolar anaphase and apoptosis in lung cancer cells with supernumerary centrosomes (known as anaphase catastrophe). We investigated a new and potent CDK2/9 inhibitor, CCT68127 (Cyclacel).Methods: CCT68127 was studied in lung cancer cells (three murine and five human) and control murine pulmonary epithelial and human immortalized bronchial epithelial cells. Robotic CCT68127 cell-based proliferation screens were used. Cells undergoing multipolar anaphase and inhibited centrosome clustering were scored. Reverse phase protein arrays (RPPAs) assessed CCT68127 effects on signaling pathways. The function of PEA15, a growth regulator highlighted by RPPAs, was analyzed. Syngeneic murine lung cancer xenografts (n = 4/group) determined CCT68127 effects on tumorigenicity and circulating tumor cell levels. All statistical tests were two-sided.Results: CCT68127 inhibited growth up to 88.5% (SD = 6.4%, P < .003) at 1 μM, induced apoptosis up to 42.6% (SD = 5.5%, P < .001) at 2 μM, and caused G1 or G2/M arrest in lung cancer cells with minimal effects on control cells (growth inhibition at 1 μM: 10.6%, SD = 3.6%, P = .32; apoptosis at 2 μM: 8.2%, SD = 1.0%, P = .22). A robotic screen found that lung cancer cells with KRAS mutation were particularly sensitive to CCT68127 ( P = .02 for IC 50 ). CCT68127 inhibited supernumerary centrosome clustering and caused anaphase catastrophe by 14.1% (SD = 3.6%, P < .009 at 1 μM). CCT68127 reduced PEA15 phosphorylation by 70% (SD = 3.0%, P = .003). The gain of PEA15 expression antagonized and its loss enhanced CCT68127-mediated growth inhibition. CCT68127 reduced lung cancer growth in vivo ( P < .001) and circulating tumor cells ( P = .004). Findings were confirmed with another CDK2/9 inhibitor, CYC065.Conclusions: Next-generation CDK2/9 inhibition elicits marked antineoplastic effects in lung cancer via anaphase catastrophe and reduced PEA15 phosphorylation.

UR - http://www.scopus.com/inward/record.url?scp=85027275593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027275593&partnerID=8YFLogxK

U2 - 10.1093/jnci/djw297

DO - 10.1093/jnci/djw297

M3 - Article

C2 - 28376145

AN - SCOPUS:85027275593

VL - 109

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 6

ER -